Promoting the Quality of Medicines (PQM)
Promoting the Quality of Medicines (PQM) serves as a primary mechanism to help USAID-supported countries strengthen their quality assurance and quality control systems to better ensure the quality of medicines that reach patients. Supported by knowledgeable staff and state-of-the-art facilities around the world, PQM strives to accomplish four key objectives: Strengthen quality assurance (QA) and quality control (QC) systems, Increase the supply of quality assured medicines, Combat the availability of substandard and counterfeit medicines, and Provide technical leadership and global advocacy.
Contribute to a 50% reduction in TB mortality and prevalence (compared to 1990 levels) by accelerating detection of TB cases and by successfully treating detected cases, as well as scaling up programmatic management of multidrug-resistant TB (MDR-TB), expanding coverage of TB/HIV interventions in coordination with PEPFAR and strengthening health systems. Support the implementation of the President’s Malaria Initiative (PMI), related malaria control programs, and malaria research activities to reduce malaria-related mortality. Develop effective malaria vaccines, new malaria treatment drugs, and targeted operations research.
- ID Projet
US-GOV-1-LR-AID-GHS-A-00-09-00003- Statut de l'activité
- 2 - Implementation
- Type d'aide
- C01 - Interventions de type projet
- % to Libéria
- 100.00
Organisations
- Accountable
- U.S. Agency for International Development
- Extending
- U.S. Agency for International Development
- Funding
- U.S. Agency for International Development
- Implementing
- United States Pharmacopeial Convention
Versements par exercice fiscal, trimestre
| Exercice fiscal |
Trimestre fiscal |
Montant (USD) |
Libéria Montant (USD) |
| 2017 |
Q1 |
297,701.50 |
297,701.50 |
| 2016 |
Q4 |
196,452.29 |
196,452.29 |
| 2016 |
Q3 |
38,133.16 |
38,133.16 |
| 2016 |
Q2 |
69,433.62 |
69,433.62 |
| 2016 |
Q1 |
41,465.96 |
41,465.96 |
| 2015 |
Q4 |
10,409.96 |
10,409.96 |
| 2015 |
Q1 |
197,025.24 |
197,025.24 |
| 2014 |
Q2 |
20,323.25 |
20,323.25 |
| 2014 |
Q1 |
8,888.26 |
8,888.26 |
| 2013 |
Q4 |
70,605.23 |
70,605.23 |
| 2013 |
Q3 |
25,204.01 |
25,204.01 |
| 2013 |
Q2 |
12,836.36 |
12,836.36 |
| 2013 |
Q1 |
18,220.19 |
18,220.19 |
| 2012 |
Q4 |
47,251.90 |
47,251.90 |
| 2012 |
Q3 |
18,356.42 |
18,356.42 |
| 2012 |
Q2 |
2,365.96 |
2,365.96 |
| 2012 |
Q1 |
2,716,439.44 |
2,716,439.44 |
| 2011 |
Q4 |
2,195,058.64 |
2,195,058.64 |
| 2011 |
Q3 |
2,209,565.96 |
2,209,565.96 |
| 2011 |
Q2 |
2,092,522.75 |
2,092,522.75 |
| 2011 |
Q1 |
2,346,754.73 |
2,346,754.73 |
| 2010 |
Q4 |
1,945,903.83 |
1,945,903.83 |
| 2010 |
Q3 |
1,578,525.27 |
1,578,525.27 |
| 2010 |
Q2 |
1,413,572.84 |
1,413,572.84 |
| 2010 |
Q1 |
460,292.42 |
460,292.42 |
| 2009 |
Q4 |
2,161,988.69 |
2,161,988.69 |
| 2009 |
Q3 |
662,358.40 |
662,358.40 |
Engagements par exercice fiscal, trimestre
| Exercice fiscal |
Trimestre fiscal |
Montant (USD) |
Libéria Montant (USD) |
| 2016 |
Q3 |
300,000.00 |
300,000.00 |
| 2015 |
Q4 |
250,000.00 |
250,000.00 |
| 2014 |
Q3 |
100,000.00 |
100,000.00 |
| 2013 |
Q2 |
150,000.00 |
150,000.00 |
| 2012 |
Q1 |
6,631,301.00 |
6,631,301.00 |
| 2011 |
Q3 |
3,650,000.00 |
3,650,000.00 |
| 2011 |
Q1 |
6,254,080.00 |
6,254,080.00 |
| 2010 |
Q4 |
300,000.00 |
300,000.00 |
| 2010 |
Q2 |
1,630,000.00 |
1,630,000.00 |
| 2010 |
Q1 |
6,928,080.00 |
6,928,080.00 |
| 2009 |
Q2 |
100,000.00 |
100,000.00 |
| 2009 |
Q1 |
6,104,317.00 |
6,104,317.00 |
Projections de CDMT par exercice fiscal
| Exercice fiscal |
Montant (USD) |
Libéria Montant (USD) |
| Code CRS |
% |
|
Lutte contre le paludisme
(12262)
|
2.47
|
|
Inconnu
(0)
|
97.53
|